digital therapeutics
In other digital health news...
Things aren't looking great in the land of digital therapeutics.
Orexo, a Swedish pharmaceutical company, did well in all areas except for digital therapeutics, the company reported in its second quarter earnings call on Tuesday. During the pandemic, Orexo invested heavily in digital products to treat opioid use disorder, problematic drinking, and depression. But it's seen no revenues from these products. Earlier this year, the company announced it would scale the apps back. Read more here.
Mental health app developer Twill is looking for a pharma partner to market Aspiro, its cognitive behavioral therapy treatment for anxiety and depression. Twill executives told Mario they hope pharma companies will be interested in pairing the digital therapeutic with a drug. Without a drugmaker partner, they won't take Aspiro to market. Read more here.
medical devices
Using noisy data for better heart wearable readings
There's a growing opportunity to screen more adults for heart disease as more people buy Apple Watches and other wearables. But wearables just aren't as good at picking up on the heart's electrical signals and rhythm as hospital-grade electrode sensors. Wearables shift on sweaty skin, or pick up outside electrical interference.
So a team of Yale researchers tried something different: training an AI algorithm on noisy electrocardiograms, electrical pulse recordings that illustrate heart function. Starting an algorithm off with this data could help it more easily adapt to real-world use. "You could say I'm going to find the clean, pristine-looking ECG that looks a lot more like the ECG done in a clinical setting, and only use those for diagnostics," study author Rohan Khera told Lizzy. "But that's not the reality. Clinical ECGs are not obtained on wristwatches." Read more here.
No comments